beta-glucosylceramide

**Beta-glucosylceramide** is a glycosphingolipid composed of a ceramide backbone (sphingosine base linked to a fatty acid via an amide bond) with a single glucose molecule attached by a β-glycosidic bond. It is an endogenous metabolite found in cellular membranes, including the plasma membrane, Golgi apparatus, and endosomes[2][8]. In the body, beta-glucosylceramide serves as a key intermediate in glycosphingolipid metabolism and is hydrolyzed by the enzyme beta-glucocerebrosidase (GBA), which breaks down beta-glucosylceramide into ceramide and glucose[5]. Beta-glucosylceramide has been studied as an immunomodulatory and immunostimulatory molecule, including experimental trials in nonalcoholic steatohepatitis (NASH) and as a biomarker or potential therapy in Gaucher disease and Parkinson’s disease[3][4][9]. Mechanistically, its biological effects include modulation of immune cell populations (particularly CD4+ T cells and NKT cells), and potential anti-inflammatory or neuroprotective actions[1][4][9]. It is being investigated as both a biomarker and a therapeutic agent, but it is not approved as a pharmaceutical drug for any indication.

Other names

β-glucosylceramideglucosylceramidebeta-D-glucosylceramidebeta-D-glucosyl-N-acylsphingosine